Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New insulin combination for type 2 diabetes gains EU approval


A new type of combination treatment, including basal insulin, is set to be launched next year after gaining European approval.

The European Commission has granted authorisation for the first ever once-daily basal insulin and GLP-1 receptor agonist in one pen for the treatment of type 2 diabetes in adults.

The product, marketed under the name Xultophy by Novo Nordisk, combines insulin degludec (Tresiba) with liraglutide (Victoza).

The authorisation covers all 27 European Union member states. Novo Nordisk said it expected to launch Xultophy in the first half of 2015.

The product is indicated for improving glycaemic control in combination with oral glucose-lowering medicinal products, when these alone or combined with basal insulin do not provide adequate glycaemic control.

New study data on the product was presented last week at the European Association for the Study of Diabetes annual meeting in Vienna.

According to data from the DUAL I and II trials, patients taking Xultophy showed an early and substantial improvement in glycaemic control – HbA1c reduction of 1.9% – and a beneficial weight profile, compared to those talking insulin degludec alone.

These benefits were demonstrated from as early as four weeks after treatment initiation in both insulin-naïve and insulin-treated patients, according to Novo Nordisk.

Xultophy-treated patients also had a greater likelihood of reaching both pre- and post-prandial blood glucose targets, compared with either insulin degludec or liraglutide, said the company.

gwen_hallGwen Hall

Gwen Hall, a diabetes specialist nurse from the Portsmouth Community Diabetes Service, noted that many diabetes patients were reluctant to increase their medication due to unwarranted side effects, such as weight gain, hypoglycaemia, or an increasing number of injections.

“The DUAL data show promise in addressing all those concerns, providing health care professionals, and people with diabetes, with a novel approach to managing their condition while minimising the impact of diabetes on their day-to-day lives,” she said.


Readers' comments (2)

  • Hmm still an injection though- patients hate them!!

    Unsuitable or offensive? Report this comment

  • Sounds promising! Look forward to trying it out. I think there is definitely a place for it as at least it's one less injection for those currently taking insulin and Victoza separately.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs